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ABSTRACT 
 
Ectodomain cleavage of cell-surface proteins by A Disintegrin And 
Metalloproteinases (ADAMs) is highly regulated, and its dysregulation has 
been l inked to many diseases. ADAM17-dependent Epidermal Growth Factor 
(EGF) pro-l igand cleavage drives mammary carcinogenesis, proliferation, 
migration and invasion of Triple Negative Breast Cancer (TNBC) cells 
both in vitro and in vivo. ADAM 17 over-expression in TNBC patients 
negatively predicts adverse outcomes in breast cancer patients and has 
recently been suggested as a novel diagnostic tool and therapeutic target.  
 
This thesis explores the potential to understand shedding regulation 
upstream of ADAM17 for ADAM17/EGFR ligand axis targeting in TNBC. The 
overall objective is to investigate the cleavage of ADAM17 substrates by 
examining the effect of enzyme inhibitors targeting different signaling 
molecules (kinases, phosphatases and cytoskeletal components) on basal 
and phorbol ester-induced ADAM17-mediated substrate cleavage and EGFR 
phosphorylation in MDA-MB-231cells.  
 
ADAM17 cleavage regulators have been identif ied as new drug targets in 
TNBC. In l ine with this objective, the role of two recently identif ied ADAM17 
dependent cleavage regulators from the lab, Protein Kinase C alpha (PKC-α) 
and Protein Phosphatase 1 Regulatory (inhibitor) subunit 14 (PPP1R14D), in 
TNBC relevant cellular responses have been evaluated. Firstly, inducible 
knockdown (KD) of these targets was achieved in the TNBC epithelial cell 
l ine MDA-MB-231 via lentiviral IPTG-inducible shRNA vector system (pLKO-
904) and its effects on migration, invasion and cell proliferation was tested 
in vitro. These in vitro results were correlated with in vivo results obtained 
by transplanting the same cells via orthoptopic mammary fat-pad 
transplantation into mice.  
 
For both approaches, Western blot analysis of total protein extracts isolated 
from whole cell lysates was used to determine the phosphorylated and total 
levels of Epidermal Growth Factor Receptor (EGFR) as well as of i ts 
downstream targets Extracellular signal-Regulated Kinases (ERKs), Protein 
Kinase B (PKB/Akt) and Signal Transducer and Activator of Transcription 3 
(STAT3). qPCR was used to study the expression levels of EGFR and of 
other Receptor Tyrosine Kinases (RTKs). ELISAs using cell culture 
supernatants were conducted to measure cleaved ADAM17 substrates such 
as soluble transforming-growth-factor-alpha (TGF-α), heparin-binding EGF 
(HB-EGF), amphiregulin, tumor-necrosis-factor-receptor-1 (TNFR1) along 
with the ADAM10 substrate R/c Met.  
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We found that the shedding regulation occurs on the substrate level and that 
Protein Kinase C (PKC) activity is essential in the regulation of EGF ligand 
cleavage. PKCα and PPP1R14D knockdown resulted in signif icantly reduced 
migration, invasion and cellular proliferation of cells, suggesting that 
targeting of PKCα and PPP1R14D could provide a therapeutic benefit in 
TNBC. Targeting cleavage regulators that address substrates instead of the 
protease could prevent the observed negative side effects of broad-
spectrum metalloprotease inhibitors in patients, which were due to non-
selective substrate cleavage inhibit ion. Since single targeted therapies, in 
particular therapies directed against the EGFR, often induce resistance, 
EGF l igand cleavage regulator targeting could be used in combination with 
direct EGFR targeting for better therapeutic benefit.  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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Extracto 
Ectodominio desdoblamiento de proteínas de la superficie celular por una 
disintegrina y metaloproteinasas (Adams) es altamente regulado, y su 
desregulación se ha vinculado a muchas enfermedades. ADAM17-
dependiente Factor de Crecimiento Epidérmico (EGF) pro-l igando unidades 
clivaje carcinogénesis mamaria, proliferación, migración e invasión de 
Cáncer de Mama Triple Negativo (TNBC) células tanto in vitro como in vivo. 
ADAM 17 de expresión de forma negativa en los pacientes TNBC predice los 
resultados adversos en pacientes con cáncer de mama y recientemente se 
ha propuesto como una nueva herramienta de diagnóstico y objetivos 
terapéuticos.  
 
Esta tesis explora el potencial para entender empaparlo anterior reglamento 
de ADAM17 En el caso de ADAM17/EGFR ligando en eje TNBC. El objetivo 
general es el de investigar la etnización de ADAM17 sustratos por examinar 
el efecto de los inhibidores de la enzima diferentes moléculas de 
señalización (kinasas, fosfatasas y del citoesqueleto componentes) en basal 
y éster de forbol inducidos por ADAM17-mediada por cl ivaje sustrato EGFR 
y la fosfori lación en MDA-MB-231células.  
 
ADAM17 escote los reguladores han sido identif icadas como nuevas dianas 
farmacológicas en TNBC. En línea con este objetivo, el papel de los dos 
identif icados recientemente ADAM17 depende de clivaje de los reguladores 
del laboratorio, la proteína quinasa C (PKC alfa-α) y proteína fosfatasa 1 
reguladores (inhibidor) subunidad 14 (PPP1R14D), TNBC pertinentes en las 
respuestas celulares han sido evaluados. En primer lugar, el tumbador 
inducible (KD) de estos objetivos se ha logrado en la línea celular epitel ial 
TNBC MDA-MB-231 lentivíricos IPTG a través de sistema de vectores 
shRNA inducible (pLKO-904) y sus efectos sobre la migración, la invasión y 
proliferación celular fue probado in vitro. Estos resultados in vitro se 
correlacionaron con los resultados obtenidos in vivo mediante el trasplante 
las mismas células mamarias orthoptopic través adiposa de trasplante en 
ratones.  
 
Para ambos enfoques, análisis de Western blot de extractos de proteínas 
totales aislados de l isados celulares todo fue uti l izado para determinar el 
nivel total y fosfori lación del receptor del factor de crecimiento epidérmico 
(EGFR, por sus siglas en inglés) así como de sus objetivos posteriores 
reguladas por señales extracelulares (l lamada Erks cuya), proteína quinasa 
B (AKT) y transductor de señal y activador de la transcripción 3 (STAT3). 
qPCR fue uti l izado para estudiar los niveles de expresión de EGFR y de 
otros receptores t irosina quinasas (RTKs). Las pruebas ELISA con 
sobrenadantes de cult ivos celulares se realizaron para medir escinde 
ADAM17 sustratos tales como soluble transformar-crecimiento-factor-alfa 
(TGF-α), de heparina EGF (HB-EGF), la anfiregulina, tumor necrosis factor 
receptor-1 de (TNFR1) junto con el sustrato ADAM10 R/c.  
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Encontramos que el derramamiento reglamento se produce sobre el sustrato 
y que la proteína quinasa C (PKC) es esencial en la regulación de cl ivaje 
l igando EGF. PKCα  y PPP1R14D el tumbador produjo una signif icativa 
disminución migración, invasión y proliferación celular de las células, lo que 
sugiere que la selección de PKCα y PPP1R14D podría proporcionar un 
beneficio terapéutico en TNBC. Dirigido a los reguladores que escote 
sustratos dirección en lugar de la proteasa podría impedir que el observado 
efectos secundarios negativos de amplio espectro inhibidores de 
metaloproteasas en pacientes, que se debieron a la no inhibición selectiva 
cl ivaje sustrato. Desde solo terapias dirigidas, en particular las terapias 
dirigidas contra el EGFR, suelen provocar resistencia, l igando EGF clivaje 
selección regulador podrían uti l izarse en combinación con los beneficiarios 
directos de EGFR mejor beneficio terapéutico.   
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1 Introduction  
 
1.1 Breast Cancer   
 
Breast cancers represent a multitude of different diseases with intra-
tumoral and inter-tumoral genetic and epigenetic alterations. Their 
heterogeneity makes them both a fascinating and challenging solid 
tumor to diagnose and treat. Breast cancer is the most common cancer 
in women. The global burden of breast cancer exceeds all other 
cancers and the incidence rates of breast cancer are increasing1.  
 
Breast cancer is a malignant tumor that can grow into (invade) 
surrounding tissues or spread (metastasize) to distant areas of the 
body. Increased risk of premenopausal breast cancer chiefly attr ibutes 
to the long-term use of oral contraceptives, low body mass index (BMI) 
and high animal fat diet consumption. Additionally, due to the decline 
in physical activity breast cancer risk in post-menopausal women has 
also increased. Family history and genetic mutations also account for 
some of the increased risks of breast cancer in premenopausal 
women2. In addition to these l isted causes, age per se is sti l l  being 
advocated as an independent risk factor for breast cancer. 
 
Breast cancer in young women is associated with adverse 
pathophysiological changes, including hormone receptor negativity as 
in tr iple-negative breast cancer. This leads to a signif icant negative 
impact on the rate of local recurrence and overall survival. Younger 
women are often diagnosed with breast cancer at an advanced stage, 
which further explains worse outcomes.  
 
This entails more aggressive treatment modalit ies and the need for 
closer monitoring and follow-up. The challenge is to understand how 
defects arise during disease progression and to learn more about the 
mechanisms of development of resistance to specif ic breast cancer 
therapies. It is of paramount importance to improve our scientif ic 
understanding of the carcinogenetic process so that treatment 
responses can be monitored and potential biomarkers for early 
detection are identif ied3. 
 
The normal breast 
 
The normal structure of the breasts helps to better understand breast 
cancer, as depicted through (Fig. 1) below. The female breast is 
mainly composed of lobules (milk-producing glands), ducts (t iny tubes 
that carry the milk from the lobules to the nipple) and stroma  (fatty 
t issue and connective tissue surrounding the ducts and lobules, blood 
vessels, and lymphatic vessels).  
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The epithelial lactiferous ducts terminate in secretory alveoli 
embedded in a f ibrous tissue framework and fat.  
 
 
F igure 1:  Anatomy of  the female breast ;  (Th is  image is  adapted f rom Nat ional  
L ibrary  of  Medic ine,  Nat ional  Ins t i tutes  of  Heal th)   
 
Most breast cancers begin in the cells that l ine the ducts (ductal 
cancers). Some begin in the cells that l ine the lobules ( lobular 
cancers), while a small fraction starts in other t issues. 
 
The lymph (lymphatic) system of the breast 
 
The lymph system is important to understand because it is one way 
breast cancers can spread. This system has several parts (Fig. 2).  
 
Lymph nodes are small, bean-shaped collections of immune system 
cells (cells that are important in f ighting infections) that are connected 
by lymphatic vessels. Lymphatic vessels are l ike small veins, except 
that they carry a clear f luid called lymph ( instead of blood) away from 
the breast. Lymph contains t issue fluid and waste products, as well as 
immune system cells. Breast cancer cells can enter lymphatic vessels 
and begin to grow in lymph nodes.  
 
Most lymphatic vessels in the breast connect to lymph nodes under the 
arm (axil lary nodes). Some lymphatic vessels connect to lymph nodes 
inside the chest ( internal mammary nodes) and either above or below 
the collarbone (supraclavicular  or infra-clavicular nodes). 
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F igure 2:  Lymph nodes in  re la t ion to the breast ;  (Th is  image is  adapted f rom the 
Amer ican Cancer Society)   
 
The more lymph nodes with breast cancer cells, the more l ikely it is to 
f ind the cancer in other organs. Because of this, f inding cancer in one 
or more regional lymph nodes often affects the treatment plan. 
However, not all women with cancer cells in their lymph nodes develop 
metastases, and some women can have no cancer cells in their lymph 
nodes and later develop metastases. 
 
Breast Biology and Susceptibility to Cancer 
 
Cells that divide are at a higher risk of acquiring mutations than cells 
that don't divide. Cancer is generally rare in t issues in which cells 
don't divide, l ike the nerve tissue. Alternatively, cancer is more 
common in t issues in which cells divide frequently such as breast, 
skin, colon and uterine tissues4. 
 
Young women and girls have breast t issue that is especially sensit ive 
to cancer causing agents (carcinogens). Unlike other t issues in the 
body l ike the l iver and the heart that are formed at birth, breast t issue 
in newborns consists of only a t iny duct. At puberty, in response to 
hormones (l ike estrogen that is secreted by the ovary) and several 
growth factors l ike f ibroblast growth factor (FGF), epidermal growth 
factor (EGF), soluble transforming-growth-factor-alpha (TGF-α) and 
amphiregulin (AREG), the breast duct grows rapidly into a tree-l ike 
structure composed of many ducts5-9.  
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Most breast development occurs between puberty and a woman's f irst 
pregnancy. After a woman's f irst ful l-term pregnancy, hormonal 
influences transform a high proportion of her breast cells into mature, 
differentiated cells, which make milk. Milk producing cells are ful ly 
mature and less sensit ive to DNA damage than immature 
undifferentiated cells4. The immature breast cells, called "stem cells", 
divide rapidly during puberty. The cells in the immature, developing 
breast are not very eff icient at repairing mutations, and they are more 
l ikely to bind carcinogens. Therefore it is important to reduce the 
exposure of young women and girls to carcinogens that might damage 
DNA during this phase of rapid breast development4.  
 
Environmental estrogens are also known to stimulate cell division in 
the breast. These are synthetic chemicals (xenoestrogens) that can act 
l ike human estrogen in a woman's body and are primarily found in 
contraceptives or industrial ized packaged foods. One such chemical, 
bisphenol, is widely used in many food-processing plastics. 
Phytoestrogens on the other hand can have a more favorable side 
effect profi le than estrogen itself and can be supplemented by diet to 
treat the symptoms of menopause.  
 
1.2 Defining the Triple-Negative Breast Cancer (TNBC) 
cohort  
  
Breast tumors are classif ied based on the expression of estrogen 
receptor (ERα), progesterone receptor (PR) and the over- 
expression/amplif ication status of HER2/ERBB2. Cancers lacking 
expression of these three proteins have been referred to as “tr iple-
negative breast cancer” (TNBC), and are associated with a poor 
prognosis and heterogeneity.  
Triple-negative breast cancer (TNBC) accounts for approximately 15% 
of all  breast cancers10.  
 
TNBC is an important area of research because: 
(1) TNBC is a poor prognostic factor for disease-free and overall 
survival,  
(2) no effective specif ic targeted therapy is readily available for TNBC; 
for example TNBC tumors are not sensit ive to targeted therapeutics 
used for HER2-posit ive (trastuzumab and lapatinib) and ERα-posit ive 
(tamoxifen and aromatase inhibitors) tumors2  
(3) there is a clustering of TNBC cases in premenopausal women and 
in women of African descent, and  
(4) the overlap of the TNBC phenotype with the basal-l ike breast 
cancer subtype (BRCA1  mutation-associated tumors) has prognostic 
signif icance due to the relative chemosensit ivity of this cancer 
subtype.  
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Patients with TNBC are also more l ikely to experience a recurrence 
within the first 3 years of diagnosis, usually with distant visceral 
metastasis, leading to an increased l ikelihood of breast cancer– 
associated mortality11-12. 
Thus, a better understanding of the biology of this disease is essential 
to improve clinical outcomes in TNBC.  
1.3 The ERBB receptors and their ligands  
 
The tyrosine-kinase epidermal growth factor receptor (EGFR/ 
ERBB1/HER1), one of the most versati le signaling units in biology, 
regulates key processes of cell biology, such as cell proliferation, 
survival and differentiation during development, t issue homeostasis 
and tumorigenesis.  
The l igands for the EGFR include epidermal growth factor (EGF), 
soluble transforming-growth-factor-alpha (TGF-α), amphiregulin, 
betacellul in, heparin-binding EGF (HB-EGF) and epiregulin4. Each of 
these l igands is produced as a type I trans-membrane precursor 
protein requiring proteolytic release of the mature growth factor 
(ectodomain shedding), which can then bind to and activate EGFR5. 
Activated EGFR/HER1 stimulates many intracellular signaling 
pathways; two of the main pathways activated by the receptors are the 
mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 
3-kinase (PI3K)–AKT pathways.  
Signal transducer and activator of transcription proteins (STATs), SRC 
tyrosine kinase (the activity of which is increased in response to EGFR 
activation) and Mammalian Target of Rapamycin (mTOR), a 
serine/threonine kinase activated downstream of PI3K−AKT are also 
other important EGFR signaling effectors.  
ADAM (a disintegrin and metalloprotease) proteins, membrane-
anchored metalloproteases, have been implicated in the shedding of 
several EGFR ligands13.  
The involvement of ADAMs in cellular processes, including processing 
of proteins, cleavage of growth factors and its ult imate downstream 
signaling cascades has been summarized in Fig. 3 .  
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Figure 3:  An overv iew of  ADAMs synthes is ,  process ing and funct ion.  Genes & Dev.  
17:  7-30,  2015  (Th is  image is  adapted f rom Darren F.  Seals  and Sara A.  
Courtneidge,  2015)  
Remarkably, mice lacking prominently in ADAM17 recapitulate several 
phenotypes of animals deficient in EGFR ligands, such as defects in 
epithelial maturation, branching morphogenesis of the lung, and 
malformed heart valves (Peschon et al., 1998; Zhao et al., 2001; Shi et 
al., 2003). This provides strong evidence for the in vivo  relevance of 
this enzyme in EGFR processing and l igand bioavailabil i ty for 
ectodomain shedding as a whole.  
Besides ADAM17, ADAM10 is the other member of the ADAM family 
that carries out induced cleavage; it primari ly responds to calcium 
signals. The classical ADAM10 substrate c-Met (or Hepatocyte growth 
factor receptor) has been l inked to proliferation and survival of breast 
tumor cells14. The fact that two ADAM metalloproteases have been 
associated with breast cancer biology and outcomes points to the fact 
that cleaved factors play a signif icant role in breast cancer 
progression. 
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1.4 HER1 activation by ectodomain shedding of EGF 
ligands 
 
Under physiological condit ions, HER1 activity is largely dependent on 
availabil i ty of cell surface expressed EGF ligand pro-forms and their 
post-translational processing15. The most important post-translational 
modification is the proteolytic release of the ectodomain of the pro-
l igand by ADAM17 or ADAM10 (depending on the EGF ligand), 
representing the active l igand (Fig. 4). 
F igure 4:  Schemat ic  representat ion of  the membrane-anchored mammal ian EGFR 
l igands.  J .  Cel l .  Phys io l .  218:  460–466,  2009 (This  image is  adapted f rom 
Schneider ,  M.  R.  and Wol f ,  E. ,  2009) 
Numerous investigations during the last decade have revealed that G-
protein-coupled receptors (GPCRs), the largest group of cell surface 
receptors, are able to uti l ize the EGFR as a downstream signaling 
partner for generating potent mitogenic signals15.  
Init ial ly described by Daub et al. (1996), EGFR transactivation by 
GPCRs was later shown to be a metalloprotease-dependent process: 
stimulation of GPCRs leads to the stimulation of a metalloprotease, 
result ing in EGFR ligand shedding and in the activation of EGFR-
downstream cascades (Prenzel et al., 1999). Since then, this 
phenomenon (also known as tr iple membrane-passing signal) has been 
l inked to the modulation of cell proliferation, apoptosis, and migration 
in a variety of cancer types and other diseases (Fischer et al., 2003).  
The ‘ ‘soluble’’ growth factor may bind and activate receptors on distant 
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cells, neighboring cells, or on the cell of i ts origin, mechanisms termed 
endocrine, paracrine or autocrine respectively (Fig. 5).  
F igure 5:  Ectodomain shedding of  EGFR l igands and i ts  consequences for  
s ignal ing,  Membrane-bound molecules can act ivate the EGFR of  neighbor cel ls  
( juxtacr ine mechanism).  Fol lowing proteoly t ic  re lease,  the solub le EGF module 
may act ivate the EGFR of  neighbor ce l ls  (paracr ine) ,  d is tant  ce l ls  (endocr ine) ,  or  
a t  the own cel l  membrane (autocr ine) .  J .  Cel l .  Phys io l .  218:  460–466,  2009 (This  
image is  adapted f rom Schneider ,  M.  R.  and Wol f ,  E. ,  2009)   
1.5 ADAM17 substrates/EGFR ligands  
 
A key step in elucidating the mechanism underlying the proteolytic 
release of EGFR ligands is the identif ication of the responsible 
sheddases. Ligands of the EGFR comprise a family of structurally and 
functionally related integral membrane proteins that can be 
proteolytically processed and released from cells (Harris et al., 2003). 
TGF-α, synthesized as a transmembrane precursor requires tumor 
necrosis factor alpha converting enzyme (TACE)/ADAM17-dependent 
proteolytic release to activate its receptor. Soluble transforming-
growth-factor-alpha (TGF-α) is also expressed more highly in tr iple-
negative breast tumors than in tumors of other subtypes. (Giricz et al., 
2013)  
The activity of tumor-necrosis-factor-receptors is controlled by 
sheddases as well. Both the cytokine TNF-α and its receptor TNFR1 
are processed predominantly by ADAM17 (Solomon et al. 1999; Reddy 
et al. 2000; Zhang et al. 2001). 
Moreover, the metalloprotease-dependent release of heparin-binding 
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EGF (HB-EGF) as well as amphiregulin from cells has been described 
as a key step in the transactivation of the EGFR by different G protein–
coupled receptors (GPCRs) (Prenzel et al., 1999; Gschwind et al., 
2003; Lemjabbar et al., 2003).  
Furthermore, ADAM17-deficient cells have been reported to be 
defective in shedding of TGF-α, HB-EGF and amphiregulin (Peschon et 
al., 1998; Merlos-Suarez et al., 2001; Sunnarborg et al., 2002).  
Interestingly, more than 54% of tr iple-negative breast tumors 
overexpress HER116. HER1 targeting has been tried unsuccessfully in 
the past. Often single-target therapies directed against HER1 induce 
resistance. One possible resistance mechanism to EGFR targeting is 
the production of soluble EGFR ligands from the tumor or from the 
adjacent stromal cells. Accordingly, i f  HER1 activity plays a role in 
TNBC, it is l ikely that l igand-driven activation of this receptor is also 
necessary. In agreement with this, a correlation between high EGFR 
activation and high ADAM17 levels has been found17. We are testing 
new ways of HER1 inhibit ion by exploring the potential for 
ADAM17/EGFR ligand axis targeting in TNBC.  
The identif ication of different EGFR ligands as substrates for ADAM10 
and ADAM17 sets the stage for the further analysis of how these 
substrates are regulated and how their substrate specif icity is 
achieved. Because proteolysis of EGFR ligands is crit ical for their 
functional activation and signaling via the EGFR, ADAM10 and 
ADAM17 substrates could be attractive targets for the design of drugs 
that modulate the action of these l igands at the substrate level, rather 
than on the protease level.  
Our idea is to target cleavage regulators that address substrates 
instead of the protease. This has the possibil i ty to prevent the 
observed negative side effects of broad-spectrum metalloprotease 
inhibitors in patients, which were due to non-selective substrate 
cleavage inhibit ion. Adding to that, this approach could also help 
identify alternative targets to direct EGFR inhibit ion in order to prevent 
resistance when using EGFR inhibit ion alone. 
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2 Objectives  
2.1 Hypothesis 
We wil l  test the hypothesis that protein kinase C (PKC) activity is 
essential for ADAM17 mediated EGF ligand cleavage in MDA-MB-231 
triple negative breast cancer (TNBC) cells.  
2.2 Aims 
-To explore the effect of enzyme inhibitors on basal and phorbol ester-
induced ADAM17 mediated substrate cleavage  
-To explore the effect of enzyme inhibitors on basal and phorbol ester-
induced EGFR phosphorylation  
-To evaluate the role of two previously identif ied ADAM17-mediated 
cleavage regulators in TNBC relevant cellular responses, for example 
in cancer cell migration, invasion and viabil i ty/proliferation  
-To determine the knockdown effect of the identif ied ADAM17-mediated 
cleavage regulators on receptor tyrosine kinase (RTK) expression  
-To generate an analogy for understanding the phenotypic 
characteristics of TNBC cells before facil i tating the knockdown of the 
cleavage regulators 
-To examine the effect of the IPTG induced knockdown of the cleavage 
regulators on kinase phosphorylation  
-To define the criteria about the incidental f indings  
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3 Materials  
 
3.1 Chemicals 
General:  
Product Name  Vendor Catalog Number 
2-Propanol Roth AE73.1 
Dimethyl-sulfoxide (DMSO) Sigma-Aldrich D2438 
Acrylamide 40% Bio-Rad 161-0148 
Ammonium Persulfate Thermo Scientif ic 17874 
Ethanol J. T. Baker 9401-33 
Ethidium Bromide 1% Fisher Scientif ic BP1302-10 
Fetal Bovine Serum (FBS) Sigma-Aldrich F1051 
Formaldehyde Sigma-Aldrich F8775 
Glacial Acetic Acid Sigma-Aldrich 320099 
Glycine Fisher Scientif ic BP381-5 
Nitrocellulose membrane Sigma-Aldrich N8267 
PBS  
(Phosphate Buffer System)  
Life Technologies 10010-031 
Penici l l in/Streptomycin GIBCO 15140 
Protease inhibitor Sigma-Aldrich P8340 
Stripping buffer Thermo 48426 
Temed Fisher 
Bioreagents 
112881 
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Tryptan blue 100 % Life Technologies 5250-061 
Tris Base Fisher Scientif ic BP1525 
Trypsin Sigma-Aldrich P8340 
Tween 20 Fisher Scientif ic BP337-100 
 
Culture media:  
Product Name Vendor Catalog Number 
DMEM GIBCO 41966 
 
3.2 Reagent Kits 
Product Name  Vendor  Catalog Number  
ClarityTM Western ECL 
substrate (Peroxide 
solution) 
Bio-rad 102030092 
ClarityTM Western ECL 
substrate 
(Luminol/Enhancer 
solution) 
Bio-rad 102030090 
SuperSignal® West 
Dura Extended 
Duration Substrate 
Thermo-Scientif ic 34075 
 
3.3 Consumables 
Product Name Vendor 
Cell culture 96 well round bottom 
plates 
BD Discovery Labware 
Cell culture round bottom plates, 
different 
sizes 
Greiner 
Conical tubes, 15ml, 50ml Greiner bio-one 
Coverglasses for microscope slides Langenbrinck 
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Eppendorf tubes, steri le, 1.5 ml, 2 ml Eppendorf 
Parafi lm M American National Can 
Pipette t ips without f i l ter, diffenrent 
sizes 
Corning 
Single use steri le syringes  B. Braun 
Tissue strainer 40μm, 70μm and 
100μm 
BD biosciences 
 
3.4 Instruments and Equipment  
Instrument Manufacturer 
Autoclave Vakulal S 3000 
ChemiDocTM system Bio-rad 
Centrifuge Eppendorf 
Electric Pipette Integra Bioscience 
Incubator Heraeus 
Ice machine Ziegra 
Light microscopes Olympus CX2 
Laminar f low hood Heraeus LaminAir 2448 
Microscope system Zeiss Axioplan 2 Imaging 
Nanodrop 1000 Peqlab 
Thermomixer Eppendorf 
Refrigerator (+4 .  C) SummitR 
Weighing scale Sartorius CL420 
 
 
!! ! 25!
3.5 Cell line  
Cell Line 
Name 
Species 
of 
Origin 
Characteristics and 
Description 
Vendor 
MDA-MB-231 Human Breast/mammary 
adherent phenotype 
Life 
Technologies 
 
3.6 Inhibitors  
Product Name Vendor Catalog 
Number 
Description 
AG1296(AG12)  Cayman 
Chemicals  
10010592 
 
Selective 
inhibitor of  
platelet-derived 
growth factor 
(PDGF) receptor 
kinase  
AG1478(AG14) Cayman 
Chemicals 
10010244 Selective 
inhibitor of   
epidermal 
growth factor 
receptor (EGFR) 
kinase 
API-2 Tocris 
Bioscience 
2151 Selective 
inhibitor of Akt 
(Protein Kinase 
B) signaling 
IPA 3 Tocris 
Bioscience 
3622 Group I p21-
activated kinase 
(PAK) inhibitor  
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Dynamin 
Inhibitor I 
(Dynasore/Dyna) 
EMD 
Chemicals, Inc. 
324410 A cell-permeable 
small molecule 
that inhibits the 
GTPase activity 
of dynamin1, 
dynamin2 and 
Drp1, the 
mitochondrial 
dynamin 
Microcystin-LR, 
Microcystis 
aeruginosa in 
Solution (MC) 
Enzo  
Lifesciences  
101043-37-2  
 
Potent inhibitor 
of protein 
phosphatase 1 
and protein 
phosphatase 2A  
PD-98059 Enzo Life 
Sciences AG 
BML-EI360-
0005 
Potent and 
selective 
inhibitor of MAP 
kinase kinase 
(MEK) 
U-O126 
 
 
Enzo Life 
Sciences AG 
 
 
BML-EI282 
 
 
Novel, 
potent and 
selective MEK 
inhibitor 
Okadaic Acid, in 
Solution (OA) 
EMD 
Biosciences, 
Inc.  
495609  Potent inhibitor 
of protein 
phosphatase 1 
and protein 
phosphatase 2A  
LY 294002 in 
Solution (LY2) 
EMD 
Biosciences, 
Inc.  
440204  Phosphatidyl 
inositol 3-kinase 
(PI3K) inhibitor  
 
 
Batimastat 
(BB94) 
 
 
Tocris 
Bioscience 
 
 
2961 
 
Potent broad 
spectrum 
metalloprotease 
inhibitor  
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Bisindolylmaleim
ide I 
(BIM 1) 
EMD 
Biosciences, 
Inc. 
203290 PKCδ or PKCγ  
inhibitor 
Gö6976 in 
Solution (GO) 
EMD 
Biosciences, 
Inc. 
365253 PKCα or PKCβ1 
inhibitor 
CaM Kinase II 
(CAMKK2) 
SantaCruz 
Biotechnology  
115044-69-4 A potent CaMKII 
inhibitor 
Brefeldin A 
(Bre)  
Tocris 
Bioscience 
1231 Reversible 
inhibitor of 
protein 
translocation 
from the 
endoplasmic 
reticulum (ER) 
to the Golgi 
apparatus 
CK-549 
(CK) 
Sigma-Aldrich  388604-55-5 Inhibitor of 
actin-related 
protein (Arp)2/3 
complex 
CKII (CK2) Tocris 
Bioscience 
5329 A potent, cell-
permeable 
Casein Kinase II 
inhibitor 
PP2 Tocris 
Bioscience 
1407 Src-family 
kinase inhibitor 
Rac1 (RAC) Tocris 
Bioscience 
3872 Reversible 
inhibitor of Rac1 
GDP/GTP 
exchange 
activity 
Rho Kinase 
(RHO) 
Tocris 
Bioscience 
2415 Rho GTPase 
inhibitor 
Rottlerin (Rottl) Tocris 
Bioscience 
1610 PKC delta 
inhibitor 
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3.7 Antibodies  
Product 
Name 
Vendor Dilution Source Catalog 
Number 
pEGFR (1068) Cell 
Signaling 
1:1000 Rabbit 2234 
Total EGFR Cell 
Signaling 
1:1000 Rabbit 2232 
pERK Cell 
Signaling 
1:1000 Rabbit 9101 
Total-ERK Cell 
Signaling 
1:1000 Rabbit 9102 
pAkt Cell 
Signaling 
1:1000 Mouse 9271 
Total-Akt Cell  
Signaling 
1:1000 Rabbit 9272 
pStat-3 Cell 
Signaling 
1:1000 Mouse 9131 
Total-Stat3 Cell 
Signaling 
1:1000 Rabbit 9132 
SB203580/p-38 Tocris 
Bioscience 
1202 p38 mitogen-
activated protein  
GW 583340 
(GW) 
Tocris 
Bioscience 
2239 Potent ADAM17 
and ADAM10 
protease 
inhibitor 
Compound E 
(Comp E) 
SantaCruz 
Biotechnology 
209986-17-4 A γ-secretase 
inhibitor 
ML 141 
(ML) 
Tocris 
Bioscience 
4266 Allosteric 
inhibitor of 
Cdc42 Rho 
GTPase 
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α-Tubulin Cell 
Signaling 
1:5,000 Mouse 2144 
 
3.8 Software  
Software Name Company Application 
Endnote X5 Thomson Reuters  Reference management 
GraphPad Prism 5.0 GraphPad 
Software, 
Inc. 
Statistical analysis and 
database 
management 
Microsoft Office 2011 Microsoft Documentation and 
Analysis 
applications 
ImageLab Bio-rad Analysis of western blots 
and gel images 
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4 Methods  
 
4.1 Cell culture  
All cells have been cult ivated at 370C with a 5% carbon dioxide 
concentration, unless otherwise stated. Cells were kept in culture a 
maximum of 5 weeks, to l imit genetic drift.  
4.1.1 Counting of cells 
Cells are stained with a 100% trypan blue solution at a ratio of 1:1 (10 
μ l  Cell suspension to 10 μ l  100% trypan blue solution). Trypan blue 
stains dead/dying cells blue, while l iving/healthy cells are not stained. 
The cells were then counted using a Neubauer chamber immediately 
after staining. Cell concentration was calculated according to 
manufacturer’s guidelines using the following equation: 
Average number of  cel ls  counted X di lut ion factor X 104 = cel ls /ml 
 
 
4.1.2 Collection of cells for experiments  
Adherent MDA-MB-231 cells were cultured in T-75 flasks unti l  a max 
confluence of 90%. At confluence point, cells were washed with PBS, 
trypsinized at 37°C for 5 minutes, or unti l  the cells detached from the 
surface of the flask. Trypsin was then neutralized with appropriate 
culture medium and cells were split into new culture f lasks or counted 
before being used for experimentation.  
 
4.1.3 Freezing and thawing cells 
All long-term cell stores were kept in a cryogenic unit in l iquid nitrogen 
at -196° C.  
Cells were collected from flasks, counted as mentioned above, 
centrifuged at 400xG for 8 minutes, after which culture media was 
removed. Cells were then re-suspended in freezing medium (90% FBS, 
10% DMSO) at a concentration 1 x 106 – 1 x 107 and pipetted into 
cryogenic freezing tubes. Tubes were then placed into freezing vessels 
containing isopropanol and stored overnight in a freezer at -80° C. Cell 
tubes were then transferred to the cryogenic storage unit for indefinite 
long-term storage.  
Thawing of long-term cell stores was done as quickly as possible to 
l imit cell exposure to toxic levels of DMSO. Cells were immediately 
thawed and the freezing media diluted with normal culture media. Then 
cell suspensions were centrifuged at 400 x G for 8 minutes, fol lowed 
by the removal of al l  media from the result ing cell pellet. Freshly 
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thawed cells were then washed once with culture media to remove any 
residual freezing media and centrifuged again. Once the wash media 
was removed from the cell pellet, cells were re-suspended in culture 
media and place in the incubator to recover from the freezing/thawing 
process.  
4.1.4 Triple Negative Breast Cancer cell line acquisition 
The MDA-MB-231 TNBC cell l ine was extracted from the human 
mammary gland/breast adenocarcinoma and was purchased by Life 
Technologies-A Thermo Fischer Scientif ic brand.  
4.1.5 Lentivirus Production and Infection  
For virus production, the following protocol was used: 800,000 
HEK293T cells were seeded in a 6-cm plate on day 0. On day 1, 50% 
confluent cells were transfected with 1 mg viral plasmid of choice, 0.9 
mg of VSVG, and 0.1 mg pUMVC (retroviral polymerase) or 0.1 mg 
deltaPVR (lentiviral polymerase) using 6 mL of FuGENE 6 (all  premixed 
in serum-free medium and incubated 20 min at room temperature). On 
day 2, 18 h after transfection, medium was changed to 4 mL medium 
containing 30% (vol/vol) FCS in DMEM. On day 3, 48 h after 
transfection, viral supernatant was harvested and syringe-fi l tered 
through a 0.4-mM fi l ter directly onto cells to be infected (50% confluent 
at point of infection). Polybrene 4 mg/mL was added to the virus, and 
infection was done by spin-infection at 750 ×  g for 30 to 60 min.  
 
4.2. shRNA knockdown screen 
IPTG inducible lentiviral shRNA vectors (pLKO904/905) were used. 
Lentiviral ly infected TNBC cells were grown for 7 days in IPTG-
containing media (100mM) to induce strong gene knockdown (typically 
established within 3-5 days; returns to normal if IPTG is withdrawn). 
The knockdown cells in vitro were re-tested for their desired 
knockdown phenotype through qPCR and/or Western blot.  
4.3. Western Blotting 
This procedure is used to measure protein levels in a particular cell of 
interest for a given experiment.  
4.3.1 Cell Lysis  
Cells were plated onto both 12-well and 6-well plates, then treated per 
experimental plan. The plates were placed on ice. When the endpoint 
of the experiment was reached and the protein extraction was needed, 
the cells were rinsed twice with phosphate buffered saline (PBS) to 
remove any media that might contribute to protein contaminants. After 
washing the cells with PBS, TNE lysis buffer containing protease and 
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phosphatase inhibitors was used to re-suspend and lyse the cells. 
Before scraping, the cells are allowed to sit for 30 minutes in the TNE 
Lysis Buffer. Cells were scraped from the plate and put into 1.5 ml 
tubes. After the lysis incubation period, this cell suspension was 
centrifuged at 10,000 x G for 10 minutes at 40C to form a cell pellet. 
The cell pellet was discarded and the cell suspension was aspirated off 
to another clean 1.5 ml tube. Volume of lysis buffer used was 
proportionate to cell number and plate size, typically 50-100 μ l .  The 
protein supernatant was stored for the protein assay.   
4.3.2 Bradford Assay  
Protein concentration of each lysate was measured to quantify specif ic 
sample concentrations based on colorimetric assay. 20 μ l  of Bio-Rad 
Protein Assay reagent S was combined with per ml of Bio-Rad Protein 
Assay reagent A. The working reagent A’ (25 μ l)  was used on 5 μ l  of 
the sample or standard protein in a 96-well f lat-bottomed plate. The 
plate was then incubated with Bio-Rad Protein Assay reagent B at 370C 
for 15 minutes. The colorimetric value was recorded using a photo 
spectrometer and analyzed with Microsoft Excel.   
4.3.3 SDS PAGE Separation  
SDS-PAGE gels had a concentration gradient from 4-12% of sodium 
dodecyl sulfate polyacrylamide gel (SDS-PAGE) for electrophoretic 
separation. Equal amounts of sample protein (30 μg) were mixed in a 
loading mixture with sample and TNE lysis buffer to a maximum volume 
of 80 μ l  to make up the loading sample and then heated to 950C for 5 
minutes. Denatured loading samples were pipetted into gel wells 
alongside a pre-stained protein standard ladder. Gels were then 
enveloped in approximately 200 ml, 1x running buffer. An electric f ield 
of 130-150V was then applied to the gel and the gel run was sustained 
for 60-90 minutes.  
4.3.4 Protein transfer to Nitrocellulose membrane  
From the gel, the proteins were blotted onto a nitrocellulose membrane 
using a 230 mA electric current for 60-90 minutes to force the proteins 
onto the membrane. This was done in a 1x transfer buffer solution with 
10% methanol. Transfer chamber was placed in a cool water bath to 
prevent overheating.  
4.3.5 Antibody Incubation  
After transfer to a nitrocellulose membrane, the membrane was 
blocked with 5% milk/Tris-buffered saline solution (TBST; 50 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 0.1% Triton) for 1 h at room temperature. 
The primary antibody was incubated overnight at 4 °C in 5% BSA/ 
TBST. This is done to prevent background staining. The membranes 
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were washed three times in TBST and then incubated with the 
respective secondary horseradish peroxidase (HRP) labeled antibody 
(1:5,000) for 1 h at room temperature in 5% (wt/vol) milk/TBST to 
detect the primary antibody. Membranes were washed 3 more times 
with TBST to remove excess secondary antibody.  
4.3.6 Chemiluminescence and Quantification  
The membranes were incubated with a chemiluminescent substrate 
(ECL) for the horseradish peroxidase for 5 minutes at room 
temperature. The membranes were exposed to the ECL and packed 
into a plastic f i lm. Then the membranes were exposed inside the 
Chemiluminescence machine in the dark. The enzymatic reaction emits 
l ight in proportion to the amount of protein present when the HRP 
oxidized the substrate, thus revealing the location and the quantity of 
the proteins, both primary and secondary antibodies, and the HRP on 
the membrane. Images of protein bands are analyzed for intensity 
using ImageLab software. Dividing the value of the band area by the 
same value of the associated loading control normalizes each protein 
band. Finally normalized protein expression values are combined to 
form a graphical representation in GraphPad Prism for analysis.  
4.4 qPCR 
4.4.1 RNA extraction 
The samples were kept on ice. 1ml of Tri-reagent were used for each 
sample. After mechanical homogenization, the sample is kept for 5 
minutes at room temperature. 0.2 ml of chloroform was added per ml of 
Tri-reagent. The samples are covered tightly and shaken vigorously for 
15 seconds and again kept on room temperature for 2-15 minutes. 
Then centrifuged at 12,000xg for 15 minutes at 2-8oC. The sample 
separated into three phases: 1) red organic phase (contained protein) 
2) inter-phase (DNA) 3) Color less upper aqueous phase (contained 
RNA). The aqueous phase was taken into a fresh tube and 0.5 ml of 2-
propanol per ml of Tri-reagent was added and mixed. It was kept for 5-
10 minutes at room temperature and centrifuged at 12000xg for 10 
minutes at 2-8oC. RNA formed a pellet at the bottom of the tube. 
Supernatant was removed and pellet was washed by 1 ml of 75% 
ethanol per 1 ml of Tri reagent. Sample was vortexed and centrifuged 
at 7500xg for 5 minutes at 2-8oC. The RNA pellet was dried at room 
temperature unti l  i t  became transparent. 10-20 μ l  of water free in DNA 
and RNA was added. The RNA concentration and purity was measured 
using the Thermo Scientif ic NanoDrop 2000 spectrophotometer.  
Samples were diluted (2 μ l  of sample+8 μ l  Mil l ipore water) and stored 
at -20oC. Simultaneously, a 396 well qPCR plate was prepared with 24 
different primers (1 μ l  each well) in tr ipl icates with occasional spin 
down in between. The qPCR plate was kept for drying over-night.  
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4.4.2 Reverse transcription  
 
RT-PCR can be done in two steps, f irst the reverse transcription and 
then the PCR reaction. The two-step protocol is usually more sensit ive 
than the one-step method; yields of rare targets may be improved by 
using the two-step procedure. 
 
The RNase Inhibitor and Reverse Transcriptase enzyme was placed on 
ice. The 10x reaction buffer, random decamers and dNTP mix was 
thawed quickly in hands and placed on ice; small 0.25 ml PCR tubes 
were used.  
 
The reaction is assembled on ice. The Reverse Transcriptase enzyme 
is added in the end.  
 
Component Stock  Final 
amount  
Experiment 
(+RT) 
Control (-RT) 
Total RNA   ~1-2 mg ~1-2 mg 
Random Decamers 50mM 5mM 2 ml 2 ml 
10X RT Buffer 10X 1X 2 ml 2 ml 
dNTP mix 2.5mM 0.5mM 4 ml 4 ml 
RNase Inhibitor 10 U/ml 10U 1 ml 1 ml 
Reverse 
Transcriptase 
100 
U/ml 
100U 1 ml 0 ml 
Nuclease-fre
water 
  x ml 
(to total of 20 
ml) 
x ml 
(to total of 20) 
ml)  
The mix is gently mixed and spinned briefly. The PCR tubes are 
incubated in the thermocycler at 45°C for 15 minutes. Either the 
reaction can be stored at –20°C or can be proceeded to the PCR 
reaction.  
 
4.4.3 Making of Master mix 
 
We considered making master mixes as we were testing multiple sets 
of primers at once. A master mix contained everything except the PCR 
primers. We tested n=19 set of primers, made a master mix enough for 
n + 1 test. The components were mixed gently and thoroughly. 22.5 μ l  
of the master mix, 1.25 µl of each of the appropriate primer were 
added at 5 µM working stock concentration. 
 
   
Component Experiment Neg Control 1 
(-RT in step 1)  
Neg Control 2 
(no template) 
RT reaction ~1-2*(n+1) mg ~1-2*(n+1) mg 0 
10X PCR Buffer 5 *(n+1) ml 5*(n+1) ml 5 *(n+1) ml 
dNTP mix 1.25*(n+1) ml 1.25*(n+1) ml 1.25*(n+1) ml 
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MgCl2 *(n+1) ml *(n+1) ml *(n+1) ml 
Taq polymerase 0.2*(n+1) ml 0.2*(n+1) ml 0.2*(n+1) ml 
Nuclease-free water Variable Variable variable 
Total Volume 100 *(n+1) ml 100*(n+1) ml 100*(n+1) ml 
 
Reactions were assembled on ice and incubated again in 
Thermocycler. 
Init ial denaturation: 94°C for 4 min 
 
30 cycles:    Denaturation at 94°C for 30 sec 
                   Annealing at 55°C for 20–30 sec  
                   Extension at 72°C for 45 sec  
                   Final extension: 72°C for 5 min 
 
Complementary DNA (cDNA) was mixed with SYBR green and 20 µl of 
each sample was added to the wells in tr ipl icates.  Immediately after, i t  
was kept in the qPCR machine for readings. Around one and half hour 
was required for one full cycle. Calculations were done using the SDS 
software.  
 
4.5 Microplate-based multiplex ELISA  
Ninety percent confluent MDA-MB-231 cells were serum deprived for 3 
hours and then treated for 30 minutes with medium containing 
inhibitors of PKC isoforms or of other kinases and other signaling 
components. Cells were treated with 100nM TPA or vehicle for 2 hours. 
At the end of the treatments, the medium from the cell culture was 
analyzed using a microplate-based multiplex ELISA, allowing the 
detection of multiple analytes at the same time in small volumes.  
4.6 Monolayer wound healing motility assay   
MDA-MB-231 TNBC cells were grown to confluence in 6-well plates 
(BD Falcon, San Jose, CA) and were scraped with a steri le 
micropipette t ip. The wound was marked and imaged immediately after 
scraping at 0 hr and then again at 24 hr later. The area of the wound 
was measured at the 0 and 24 hr t ime points and results were 
presented as percentage of wound closure at 24 hr as compared to 0 
hours.  
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4.7 Invasion Assay  
Invasion was assessed using confocal microscopy to determine the 
distance cells travelled from the bottom of a culture vessel into a 
superimposed layer of collagen-containing media. Unlabeled cells were 
mixed with 2.2 mg/mL pH-neutralized, acid-extracted collagen I at 
500,000 cells/mL. 50mL of cell/collagen solution was placed in a f lat-
bottom polystyrene 96-well plate, spun for 5min at 300g and 
polymerized for 30min at 37oC. Gels were then bathed in 50ml ful l  
serum media. After 24hr incubation, gels were fixed with 4% 
paraformaldehyde for 2 hours and then stained with propidium iodide 
(1mg/ml) in 0.5% BSA and 0.2% TritonX-100 overnight. Confocal image 
stacks were acquired at 10X with a Nikon 1AR Ultra-Fast Spectral 
Scanning Confocal Microscope (every 5 mm) and images were 
analyzed in Matlab (Mathworks; Natick, MA) using a modified spot-
f inding algorithm. Reported invasion describes over 400 individual cells 
for each condition, across multiple (at minimum three) micro-titer wells. !
4.8 Statistical Analysis  
All data analysis was performed using GraphPad Prism version 5.03. 
Averages were calculated and graphs were plotted enclosing the 
Standard Error of the Mean (SEM) values.  
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5 Results and Discussion   
 
5.1 Effect of enzyme inhibitors on basal and phorbol 
ester-induced ADAM17 mediated substrate cleavage  
Our target of interest, ADAM17, is documented to be over-expressed in 
TNBCs.  
Furthermore, ADAM17-dependent EGF l igand cleavage drives 
mammary carcinogenesis, proliferation, migration and invasion of 
TNBC cells in vitro (our unpublished data).  
Several ADAM17 substrates are known to play important roles in TNBC 
biology, including the EGF ligands transforming-growth-factor-alpha 
(TGF-α), heparin-binding EGF (HB-EGF) and amphiregulin (Areg), as 
well as tumor-necrosis-factor-receptor-1 (TNFR1). The ADAM10 
substrate R/c Met (also named Hepatocyte-growth-factor-receptor) has 
been reported to promote breast tumor growth and plays important 
roles in resistance of some breast tumors to HER1 targeting. 
To better understand shedding regulation upstream of ADAM17 and to 
answer the question whether PKC activity is generally involved in the 
regulation of EGF l igand cleavage, we decided to investigate the 
cleavage of f ive different ADAM substrates. We measured the cleaved 
forms of TGF-α, HB-EGF, Areg, TNFR1 and R/c Met under basal or 
after phorbol ester stimulation in MDA-MB-231 TNBC cells.  
The phorbol ester TPA (12-O-Tetradecanoylphorbol-13-acetate), also 
commonly known as phorbol 12-myristate 13-acetate (PMA), is a 
diester of phorbol, often employed in shedding studies as a cleavage 
stimulus to activate the signal transduction enzyme protein kinase C 
(PKC) isoforms (-α, -β, -γ ,  -δ, -e, -η, -θ and -μ). TPA effects on PKC 
result from its similarity to one of the natural activators of classic PKC 
isoforms, diacylglycerol. The physiological effector of TPA is ADAM17, 
whereas under physiological condit ions ADAM10 primarily responds to 
calcium signals.  
Cleavage is measured with an extensively validated high-throughput 
96-well ELISA assay in biological duplicates in human MDA-MB-231 
(tr iple-negative breast cancer) cells. Ninety percent confluent MDA-
MB-231 cells are serum deprived for 3 hours and then treated for 30 
minutes with medium containing inhibitors of PKC isoforms or of other 
kinases and other signaling components. Cells are then treated with 
100nM TPA or vehicle for 2 hours.  
At the end of the treatments, the medium from the cell culture is 
analyzed using a microplate-based multiplex ELISA, allowing the 
detection of multiple analytes at the same time in small volumes.  
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The data are presented as % of control (DMSO) concentration. 
Figure  1:  Basal  ADAM17-mediated cleavage  in MDA-MB-231 TNBC ce l ls .  
Solub le l igand concentrat ion is  measured in  cel l  cul ture supernatant  by ELISA. The 
data are presented as % of  contro l  (DMSO) concentrat ion .  TNFR1= tumor-
necros is - factor- receptor-1,HB-EGF= hepar in-b inding EGF, Areg= amphiregul in ,  R/c  
Met= Hepatocyte growth factor  receptor  (HGFR),  TGF-α= solub le t ransforming-
growth- factor-a lpha.  Th is  graph represents  average data of  two independent  
exper iments  ± SEM. 
Basal Cleavage involves PKC activity: Basal cleavage of al l  the 
examined substrates is reduced in the presence of the broad-spectrum 
metalloprotease inhibitor BB94, compared to the cleavage in the 
presence of the vehicle (DMSO) (Fig. 1). This result confirms that the 
cleavage of the studied substrates is mediated by metalloproteases 
and serves as a validation for this experiment.  
BIM1, a classical PKC inhibitor results in only moderate reduction of 
AREG cleavage. However, Gö6983, a specif ic inhibitor of PKCα and β1 
isoform, results in a strong reduction of al l  ADAM17 substrates 
examined (TNFR1, TGF-α, HB-EGF and AREG). This suggests that 
either BIM1 is less effective in inhibit ing these kinases than Gö6983, 
or that some isoforms (PKCα or PKCβ1 or both) induce cleavage while 
other isoforms (such as PKCδ or PKCγ) inhibit cleavage.  
SB203580 (SB) and UO126, the two potent MAPK cascade inhibitors 
(targeting p38-MAPK and MEK1/2 respectively) also caused dramatic 
lowering of al l  examined ADAM17 substrates. Indeed, p38 
phosphorylation of ADAM17 C-terminal tai l  has been described and 
enhances cleavage by increasing surface levels of ADAM17. 
Furthermore, PP2, a Src-kinase inhibitor, not only mimics the effect 
shown by SB203580 (SB) and UO126 but also causes signif icant 
reduction of R/c Met cleavage compared to the cleavage in the 
presence of the vehicle (DMSO). 
Additionally, AG1296 and AG1478, the selective inhibitors of platelet-
derived growth factor (PDGF) receptor kinase and epidermal growth 
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factor receptor (EGFR) kinase respectively show remarkable reduction 
in HB-EGF cleavage.  
BrefeldinA (BrefA), the reversible inhibitor of protein translocation from 
the endoplasmic reticulum (ER) to the Golgi apparatus also causes 
similar reduction in HB-EGF.  
It seems therefore, that substrate specif icity exists, indicated by a 
differential effect of a given inhibitor on basal cleavage of different 
tested ADAM substrates.  
Figure  2:  Phorbol  este r-induced ADAM17-mediated cleavage  in MDA-MB-231 
TNBC ce l ls .  Solub le l igand concentrat ion is  measured in  ce l l  cul ture supernatant  
by ELISA. The data are presented as % of  contro l  (DMSO+TPA) concentrat ion.  
TNFR1= tumor-necros is - factor- receptor-1,  HB-EGF= hepar in-b inding EGF, Areg= 
amphiregul in ,  R/c  Met= Hepatocyte growth factor  receptor  (HGFR),  TGF-α= solub le 
t ransforming-growth- factor-a lpha.  Th is  graph represents  average data of  two 
independent  exper iments  ± SEM. 
Phorbol ester-induced cleavage depends on classical PKCs: 
Similar to basal cleavage, BB94 strongly decreases TPA induced 
cleavage of al l  studied substrates ,  compared to the cleavage in the 
presence of the vehicle (DMSO) (Fig. 2), thus demonstrating the role 
of metalloproteases in the cleavage of these substrates.  
TPA-induced cleavage of al l  EGF l igands is sensit ive to inhibit ion of 
classical PKCs by BIM1.  It is interesting that, although BIM1 had a 
minor effect on substrate cleavage under basal condit ions (Fig. 1), i t  
expectedly inhibited the TPA-induced cleavage of al l  the examined 
substrates profoundly.  
The effect of Gö6983 resulted in strong reduction of induced HB-EGF 
cleavage, similar to the basal conditions. Nevertheless, in contrast to 
basal conditions, i t did not inhibit TNFR1, TGF-α and Areg. Therefore, 
PKCα or PKCβ1 seem to mediate the TPA-induced cleavage of only 
HB-EGF.  
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Rottlerin, reported to inhibit mainly PKC delta isoforms showed l i tt le 
effects on substrate cleavage. 
BrefeldinA (BrefA), in contrast to the effect under basal, where there 
was signif icant reduction in HB-EGF cleavage, upon TPA stimulation, 
BrefA failed to arrest the cleavage of HB-EGF. On the contrary, API2, a 
potent inhibitor of Akt (protein kinase B) signaling markedly reduced 
TPA-induced TNFR1 and HB-EGF cleavage.  
Even though SB203580 (SB) and UO126 have dramatic lowering 
effects on all substrates under basal condit ions, surprisingly, in the 
presence of TPA, there was a pronounced increase in the levels of al l  
cleaved substrates. The same was true for the EGFR inhibitor AG1296 
and the EGFR inhibitor AG1478, as compared to vehicle control. 
Adding to that, PP2 also showed the same group. This suggests that 
cleavage under basal or TPA-stimulated conditions is probably 
regulated, at least in part, via different pathways (Fig. 2).  
It appears that the differential effect of a given inhibitor in the 
cleavage of different substrates in the TPA-induced state depends on 
specif icity at the substrate level.  
In order to better visualize the above-described data, we created heat 
maps using the Multiexperiment Viewer MeV_4.8 software. This 
program is a versati le analysis tool incorporating sophisticated 
algorithms for clustering, visualization and classif ication of the data. 
MeV generates informative and interrelated displays of expression and 
annotation data from single or multiple experiments.  
We used hierarchical clustering to group inhibitor effects that are 
represented by similar colors in order to conceive a better portrayal of 
the ELISA results.  
The heat maps below represent average data of two independent 
experiments ± SEM (Fig. 3 and Fig. 4).  
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Figure  3:  Heat map of  basal  c leavage  of  se lect ive  substrates with a  pane l  of  
inhibitors.  Green represents  reduced basal  c leavage whereas red represents  
increased basal  c leavage in  the presence of  inh ib i tors .  B lack represents  100 % of  
contro l  (DMSO) concentrat ion in  the absence of  inh ib i tors .   
Figure  4:  Heat map of  phorbol este r-induced cleavage  of  se lect ive  substrates 
with a  pane l  of  inhibitors.  Green represents  reduced TPA- induced c leavage 
whereas red represents  increased TPA- induced c leavage in  the presence of  
inh ib i tors .  B lack represents  100 % of  contro l  (DMSO+TPA) concentrat ion in  the 
absence of  inh ib i tors .   
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Apart from leading to similar conclusions regarding the effect of each 
inhibitor on basal or TPA-induced cleavage, the heat map view helps 
us to make a few addit ional observations:  
Firstly we can more clearly identify the inhibitors that result in 
differential effects on cleavage and the substrates that they mainly 
affect. For example, Rottlerin caused increased basal cleavage of 
TNFR1, TGF-α, AREG and R/c Met, but not of HB-EGF cleavage (Fig. 
3 .  
Secondly we can cluster the inhibitors based on their effect and thus 
observe similarit ies between different pathways. For example, 
BrefeldinA (BrefA), Gö6983, SB, UO126, PP2 and BB94 showed very 
low basal cleavage of al l ADAM17 substrates (Fig. 3) whereas 
SB203580 (SB), UO126 and PP2 showed increased TPA-induced 
cleavage (Fig. 4).  
It also seems that signaling molecules that are downstream of EGFR 
activation (such as ERK, p38 and Src) mediate basal ADAM17-
dependent cleavage, thus implying a possible posit ive feedback loop 
between EGFR activation and cleavage of i ts l igands.   
In summary, cleavage of some pro-EGF ligands requires the activity of 
several PKC isoforms depending on the cleavage stimulus. The 
inhibitor experiments suggest that PKC-dependent and -independent 
signaling pathways modulate EGF ligand cleavage in MDA-MB-231 
TNBC cells in a substrate specif ic way.  
5.2 Effect of enzyme inhibitors on basal and phorbol 
ester-induced EGFR phosphorylation in MDA-MB-231cells 
In addition to substrate cleavage, we examined the effect of different 
EGF l igands on EGFR phosphorylation, as well as on its downstream 
targets. Similarly to the ELISA experiments, pathway activation is 
measured with a 24-well inhibitor assay in biological duplicates in 
human MDA-MB-231 (tr iple-negative breast cancer) cells.  
First, ninety percent confluent MDA-MB-231 TNBC WT cells are plated 
2.5 x105 cells per 1.9 cm2 plate. The cells are serum deprived for 3 
hours and then incubated with 1 μg/ml of medium containing inhibitors 
of PKC isoforms or of other kinases and cytoskeletal elements for 30 
minutes.  
The concentrations and dilution factors of each inhibitor are 
standardized before the experiment. After the 3-hour serum starvation, 
cells are treated with 100nM TPA or vehicle for 2 hours.  
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At the end of the treatments, the plates are kept on ice to terminate 
the reaction. Cell lysates are prepared and the levels of 
phosphorylated, hence activated EGFR (Y1068) are determined by 
immunoblot analysis in all groups. In addition we examined the 
phosphorylation levels of ERK1/2, a major downstream effector of 
EGFR. 
pEGFR and pERK signals are subjected to densitometric analysis, 
corrected for tubulin (which is used as loading control) and are 
presented as % control (DMSO). 
Figure  5:  Weste rn blot  analysis of  MDA-MB-231 TNBC ce l l  lysates,  using 
pEGFR rabbit  ant ibody.  P lus  and minus s igns next  to  the symbol  of  the inh ib i tor  
ind icates  the presence or  absence of  TPA respect ive ly .  Tubul in  is  used as loading 
contro l .  Th is  graph represents  average data of  two independent  exper iments  ± 
SEM.  
The selective inhibitor of p38 mitogen-activated protein kinase 
p38/SB203580 along with PD98059 and UO126 show li tt le or negligible 
effect on EGFR phosphorylation as compared to the vehicle (DMSO) 
(Fig. 5). This suggests that these inhibitors do not modulate EGFR 
phosphorylation.  
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Figure  6:  Weste rn blot  analysis of  MDA-MB-231 TNBC ce l l  lysates,  using 
pERK rabbit  ant ibody.  P lus  and minus s igns next  to  the symbol  of  the inh ib i tor  
ind icates  the presence or  absence of  TPA respect ive ly .  Tubul in  is  used as  loading 
contro l .  Th is  graph represents  average data of  two independent  exper iments  ± 
SEM.  
However, PD98059 and UO126, as potent MEK1/2 inhibitors, 
downregulate MAP kinase (ERK) activity, thus validating their 
effectiveness (Fig. 6).  
 
Figure  7:  Weste rn blot  analysis of  MDA-MB-231 TNBC ce l l  lysates,  using 
pEGFR rabbit  ant ibody.  P lus  and minus s igns next  to  the symbol  of  the inh ib i tor  
ind icates  the presence or  absence of  TPA respect ive ly .  Tubul in  is  used as loading 
contro l .  Th is  graph represents  average data of  two independent  exper iments  ± 
SEM. 
As expected, BIM1, Gö6983 and BB94 caused signif icant reduction in 
EGFR phosphorylation upon TPA stimulation as compared to the 
vehicle (DMSO) (Fig. 7). Even under unstimulated conditions, BB94 
showed less EGFR activation, which further suggests the pivotal role of 
metalloproteases in EGFR phosphorylation and downstream signaling 
(Fig. 7).  
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Figure  8:  Weste rn blot  analysis of  MDA-MB-231 TNBC ce l l  lysates,  using 
pEGFR rabbit  ant ibody.  P lus  and minus s igns next  to  the symbol  of  the inh ib i tor  
ind icates  the presence or  absence of  TPA respect ive ly .  Tubul in  is  used as  loading 
contro l .  Th is  graph represents  average data of  two independent  exper iments  ± 
SEM. 
Under both TPA stimulated and unstimulated condit ions, API2, a 
selective inhibitor of Akt (protein kinase B), IPA3, a p21-activated 
kinase (PAK) inhibitor ( inhibits PAK1-mediated signaling) or an 
inhibitor of CAMKK2, (calcium/calmodulin-dependent protein kinase II 
(CaMKII)) showed no signif icant decrease in pEGFR as compared to 
control (DMSO) (Fig. 8). 
F igure  9:  Weste rn blot  analysis of  MDA-MB-231 TNBC ce l l  lysates,  using 
pEGFR rabbit  ant ibody.  P lus  and minus s igns next  to  the symbol  of  the inh ib i tor  
ind icates  the presence or  absence of  TPA respect ive ly .  Tubul in  is  used as  loading 
contro l .  Th is  graph represents  average data of  two independent  exper iments  ± 
SEM. 
A potent, cell-permeable Casein Kinase II inhibitor (CK2) fai led to 
show marked differences in EGF receptor phosphorylation as 
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compared to the control (DMSO) (Fig. 9). However, interestingly, both 
the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 and the 
Src-family kinase inhibitor PP2 lead to signif icant reduction in EGFR 
phosphorylation (Fig. 9).  
Figure  10:  Weste rn blot  analysis of  MDA-MB-231 TNBC ce l l  lysates,  using 
pERK rabbit  ant ibody.  P lus  and minus s igns next  to  the symbol  of  the inh ib i tor  
ind icates  the presence or  absence of  TPA respect ive ly .  Tubul in  is  used as  loading 
contro l .  Th is  graph represents  average data of  two independent  exper iments  ± 
SEM. 
LY294002 and PP2 also signif icantly downregulated MAP kinase (ERK) 
activity (Fig. 10).  
Figure  11:  Weste rn blot  analysis of  MDA-MB-231 TNBC ce l l  lysates,  using 
pEGFR rabbit  ant ibody.  P lus  and minus s igns next  to  the symbol  of  the inh ib i tor  
ind icates  the presence or  absence of  TPA respect ive ly .  Tubul in  is  used as  loading 
contro l .  Th is  graph represents  average data of  two independent  exper iments  ± 
SEM. 
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GW 583340, the potent dual ADAM17/ADAM10 protease inhibitor 
completely abolished pEGFR phosphorylation (Fig. 11).  
However, the allosteric inhibitor of Cdc42 GTPase ML141 failed to 
hinder EGF receptor activation. Also the reversible inhibitor of Rac1 
GDP/GTP exchange activity did not inhibit EGF receptor activation as 
compared to DMSO under both basal and TPA stimulation (Fig. 11).  
Figure  12:  Weste rn blot  analysis of  MDA-MB-231 TNBC ce l l  lysates,  using 
pEGFR rabbit  ant ibody.  P lus  and minus s igns next  to  the symbol  of  the inh ib i tor  
ind icates  the presence or  absence of  TPA respect ive ly .  Tubul in  is  used as  loading 
contro l .  Th is  graph represents  average data of  two independent  exper iments  ± 
SEM. 
As expected, AG1478 almost completely inhibited EGFR 
phosphorylation as compared to DMSO in both basal and stimulated 
conditions (Fig. 12).  
Effects of Okadaic acid and CK-549 were insignif icant (Fig. 12).  
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Figure  13:  Weste rn blot  analysis of  MDA-MB-231 TNBC ce l l  lysates,  using 
pEGFR rabbit  ant ibody.  P lus  and minus s igns next  to  the symbol  of  the inh ib i tor  
ind icates  the presence or  absence of  TPA respect ive ly .  Tubul in  is  used as  loading 
contro l .  Th is  graph represents  average data of  two independent  exper iments  ± 
SEM. 
Although AG1296 showed dramatic reduction in cleaved ADAM17 
substrates under basal condit ions (Fig. 1), EGF receptor 
phosphorylation was found increased as compared to DMSO (Fig. 13). 
Rho GTPase and Microcystin (MC) were found to have no effect on 
EGFR activation (Fig. 13). 
Figure  14:  Weste rn blot  analysis of  MDA-MB-231 TNBC ce l l  lysates,  using 
pEGFR rabbit  ant ibody.  P lus  and minus s igns next  to  the symbol  of  the inh ib i tor  
ind icates  the presence or  absence of  TPA respect ive ly .  Tubul in  is  used as  loading 
contro l .  Th is  graph represents  average data of  two independent  exper iments  ± 
SEM. 
Dynasore, a cell-permeable inhibitor of Dynamin (Dyna) and BrefeldinA 
(BrefA) also did not inhibit EGFR phosphorylation.  
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In contrast, Compound E, a γ-secretase inhibitor (Comp E) showed 
signif icant reduction of EGF receptor activation as compared to DMSO, 
both under basal and TPA stimulation (Fig. 14).  
In summary, and as described above, both ELISA detection of soluble 
ectodomain, as well as the immunoblot analysis confirmed that protein 
kinase C (PKC) isoforms are involved in EGF ligand cleavage. In 
addit ion, PKC involvement is supported by the following findings: 
!  Previous ly  in  the lab,  a  large shRNA screen target ing human phosphatases 
and k inases ident i f ied Prote in  K inase C a lpha (PKC-α )  and Prote in  
Phosphatase 1 Regulatory  ( inh ib i tor)  subuni t  14 (PPP1R14D) as  regulators  
of  TPA- induced TGF-α  c leavage (Dang et  a l . ,  2011;  Herr l ich et  a l . ,  2008)  
!  PPP1R14D is  a  PKC-act ivated speci f ic  prote in  phosphatase 1 inh ib i tor  (L iu 
et  a l . ,  2004) .  
!  In  addi t ion,  substra te speci f ic  ro les  for  some s ignal ing molecules  were 
ident i f ied,  for  example Gö6983 and BIM1 under TPA s t imulat ion had notab ly  
d is t inct  substra te spec i f ic i t ies .  As γ -secretase act iv i ty  is  regulated by 
Prote in  k inase C (PKC),  Compound E inh ib i tor  fur ther  conf i rmed our  in i t ia l  
hypothes is .   
 
In order to further evaluate the role of these two previously identif ied 
ADAM17-mediated cleavage regulators in TNBC relevant cellular 
responses, shRNA-targeted TNBC cells were studied in vitro. 
5.3 PKCα and PPP1R14D knockdown in MDA-MB-231 cells 
attenuates cell migration  
To better understand the signaling network perturbations that 
potential ly mediate resistance, inducible knockdown (KD) of PKCα and 
PPP1R14D was achieved in the TNBC epithelial cell l ine MDA-MB-231 
via lentiviral IPTG-inducible shRNA vector system (pLKO-904). The 
TNBC cell l ines were cultured in Dulbecco’s modified eagle medium 
(DMEM) with 10% FBS. Puromycin (2 μg/ml) was added to the culture 
medium for selection of cells that express the lentiviral construct and 
cells are maintained with media changes or trypsinization every other 
day.  
Lentiviral ly infected TNBC cells were grown for 5 days in IPTG-
containing media (100mM) to induce strong gene knockdown 
(established within 3-5 days; returns to normal if IPTG is withdrawn). 
The knockdown cells in vitro were re-tested for their desired 
knockdown phenotype through qPCR and/or Western blot prior to 
experiments.  
The effects on cell migration were assessed by a Monolayer wound 
healing scratch assay (Fig. 15). MDA-MB-231 TNBC cells were grown 
to confluence in 6-well plates (BD Falcon, San Jose, CA) and were 
scraped with a steri le micropipette t ip. The wound was marked and 
imaged immediately after scraping at 0 hr and then again at 24 hr later.  
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The area of the wound was measured at the 0 and 24 hr t ime points 
and results were presented as percentage of wound closure at 24 hr as 
compared to 0 hours.  
EGF l igand HB-EGF (100 μg/ml) was added in rescue experiments 
(Fig. 16). BB94 was also added as a control in a subset of 
experiments.  
Representative experimental data for MDA-MB-231 cells are shown in 
(Fig. 15) and quantitative data for the same are shown in (Fig. 16).  
Figure  15:  Wound heal ing moti l i ty  assay showing that  sh-PKCα  or  sh-
PPP1R14D   knockdown in MDA-MB-231 TNBC ce l ls  e ff ic iently  prevents 
migrat ion over a  24-hr period .  Dashed l ines  ind icate the pos i t ion of  the 
boundar ies  of  the scratched wound at  0  hr .   
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Figure  16:  Quanti f icat ion of  the  wound heal ing moti l i ty  assay for  control  (sh-
Co),  PKCα  (sh1-PKCα )  or  PPP1R14D (sh1-PPP1R14D) knockdown in MDA-MB-
231 TNBC ce l ls  w i thout  s t imulat ion (Co) or  in  the presence of  bat imastat  (BB94) 
or  HB-EGF (*p<0.05,**p<0.01 and ***p< 0.001).  Th is  graph represents  average 
data of  three independent  exper iments  ± SEM. 
We observed a signif icant suppression of tumor cell moti l i ty in PKCα 
and PPP1R14D knockdown MDA-MB-231 TNBC cells compared with 
control cells (sh-Co) (Fig. 15 , 16 , compare columns “Co” in Fig. 16). 
This inhibit ion was rescued by addit ion of EGF ligand/TACE substrate 
HB-EGF suggesting that HB-EGF release might play a signif icant role 
in TNBC cell migration (Fig. 16 , columns HB-EGF).  
As expected, the broad-spectrum metalloprotease inhibitor BB94 
reduced migration of al l  cell l ines, demonstrating that migration 
depended on metalloproteases (Fig. 16 , columns BB94). Interestingly, 
however, BB94 did not result in an additional reduction of migration in 
the PKCα and PPP1R14D knockdown cells. The latter data confirm that 
metalloprotease and PKCα/PPP1R14D are part of the same cleavage 
regulatory pathway.  
To evaluate a more physiologically relevant mode of tumor cell 
migration, we next tested the abil i ty of these cell l ines to migrate 
through a collagen gel matrix.  
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5.4 PKCα and PPP1R14D knockdown in MDA-MB-231 cells 
recapitulates cancer cell invasion  
MDA-MB-231 cells with PKCα/PPP1R14D knockdown were grown to 
70% confluence.  
Figure  17:  Schematic representat ion of  a  96-we l l  ce l l  seeded col lagen ge l-
matr ix:  quant i f icat ion of  the upward movement of  invas ive cel ls  through the 
col lagen gel  matr ix  by a confocal  microscope  
For the invasion assay (Fig. 17), an acidic solution of collagen was 
first neutralized with 0.1M NaOH. Once the desired pH of 7.4 was 
obtained, the collagen solution was kept on ice to prevent 
polymerization. The cells were trypsinized and counted. A total of 5.0 x 
103 cells/well were used per well of a 96 well plate. The collagen 
solution was then mixed with gentle pipetting with the cell suspension. 
A quick spin down of the plate at 4oC was performed to make the cells 
settle down at the bottom of the plate. The cell seeded collagen plate 
was then allowed to solidify in a humidif ied cell culture incubator at 
37oC and then DMEM with 10% FBS was added on top of the gel as a 
chemoattractant. After 24 hours, f ixation and staining with a 
f luorescent nuclear dye was done. The invading cells were quantif ied 
in each well using a confocal microscope and appropriate software. 
Each experiment was performed in duplicate. 
We evaluated the impact of PKCα and PPP1R14D knockdown on tumor 
cell invasion and the results were expressed as fold over control 
knockdown.  
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Figure  18:  Quanti f icat ion of  re lat ive  invasion depth through col lagen matr ix 
over a  24-hr period for  control  (sh-Co),  PKCα  (sh-PKCalpha) or  PPP1R14D (sh-
PPP1R14D) knockdown in MDA-MB-231 TNBC ce l ls .  A  neutra l iz ing ant i -
amphiregul in  ant ibody (ant i -AR-Ab) suppresses invas ion in  w i ld  type cel ls  (*p  < 
0.05) .  Th is  graph represents  average data of  two independent  exper iments  ± SEM. 
We observed a signif icant reduction in cancer cell invasion of MDA-
MB-231 TNBC cells with PKCα/PPP1R14D knockdown compared to 
control cells (sh-Co)(Fig. 18 , compare left panel “sh-Co” with “sh-
PKCalpha” and “sh-PPP1R14D”). A neutralizing anti-amphiregulin 
antibody greatly inhibited invasion by blocking the activity of cleaved 
amphiregulin, thus confirming that the ADAM17 substrate and EGF 
ligand amphiregulin plays a crucial role in cancer cell invasion (Fig. 
18 , r ight columns “Control” and “anti-AR-Ab”)  
Another important cellular aspect of a cancer cell is growth and 
proliferation. Therefore, we next examined the abil i ty of PKCα and 
PPP1R14D knockdown in growth and proliferation of cancer cells.  
5.5 Cell viability of PKCα and PPP1R14D knockdown in 
MDA-MB-231 cells 
The effect of PKCα and PPP1R14D knockdown on cell growth in MDA-
MB-231 TNBC cells was monitored by cell counting every 24 hours. 
Cells were stained with a 100% trypan blue solution at a ratio of 1:1 
(10 μ l  Cells to 10 μ l  100% trypan blue solution).  
Trypan blue stains dead/dying cells blue, while l iving/healthy cells are 
not stained. The cells are then counted using a Neubauer chamber 
immediately after staining (Fig. 19). 
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Figure  19:  Quanti f icat ion of  ce l l  growth for  control  (sh-Co),  PKCα  (sh1-
PKCalpha) or  PPP1R14D (sh1-PPP1R14D) knockdown in MDA-MB-231 TNBC 
ce l ls  under basal  growth condit ions (*p<0.05,**p<0.01 and ***p< 0.001).  Th is  
graph represents  average data of  three independent  exper iments  ± SEM. 
The PKCα  knockdown did not inhibit cancer cell growth, as compared 
with control cells (sh-Co).  
However, PPP1R14D knockdown resulted in a strong reduction in cell 
growth of MDA-MB-231 cells and was already signif icant after 5 days 
of knockdown induction (Fig. 19). The fact that PKCα knockdown did 
not affect cell growth, while PPP1R14D knockdown had a big effect 
suggests that other PKC isoforms may substitute for the effect PKCα in 
PPP1R14D activation.   
Our data thus far is consistent with the init ial proposit ion that PKC 
activity is essential for EGF ligand cleavage, the latter l iberated 
through ADAM17 for EGFR pathway activation.  
In parallel the same cell l ines studied in vitro were used to induce 
breast tumors in  vivo using a mouse xenograft model. In contrast to the 
in vitro data, in which PKCα and PPP1R14D knockdown resulted in 
reduced migration, invasion and/or proliferation, knockdown of the 
same genes had opposite effects in vivo.  
In particular, both knockdowns resulted in increased tumor size and 
increased metastasis as well as increased mitogenic pathway 
activation (such as ERK1/2).  
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This result resembles previous approaches to target EGFR or other 
receptors in vivo  (Moritz et al., 2010) which resulted in activation of 
alternative growth pathways, for example via the upregulation of 
alternative receptor tyrosine kinases (RTKs).  
Therefore, i t is possible that knockdown or PKCα or PPP1R14D led to 
the upregulation of alternate RTKs that provide growth signals during 
EGFR/EGF Ligand cleavage inhibit ion. In order to f ind RTKs that are 
feeding into re-activation of mitogenic pathways, the expression level 
of a panel of RTKs previously shown to mediate resistance in cancer 
was analyzed by qPCR in MDA-MB-231 cells. To determine whether 
these RTKs were upregulated already in vitro as a result of knockdown 
and not only after transplantation into mice via host-tumor interactions, 
both short term (5 days) and long term (30 and 35 days similar to the 
in vivo experiments) IPTG-induced knockdown of PKCα and PPP1R14D 
was tested in vitro.    
5.6 PKCα and PPP1R14D knockdown effect on receptor 
tyrosine kinases (RTKs) expression in vitro  
The expression levels of alternative receptor tyrosine kinases (RTKs) 
were tested with quantitative PCR. RNA was extracted from PKCα and 
PPP1R14D knockdown cells. The concentration and purity of the RNA 
was measured using the Thermo Scientif ic NanoDrop 2000 
spectrophotometer. QIAGEN Kits were used for both reverse 
transcription and PCR amplif ication. RTK expression levels were 
calculated using the Delta-Delta Ct method. Representative data are 
shown as log2fold change over individual Day 0 of each knockdown 
phenotype (Fig. 20 and Fig. 21). 
Figure  20:  Graphical  representat ion of  mRNA expression leve ls of  dif fe rent 
RTKs in the  sh-PKCα  knockdown in MDA-MB-231 ce l ls .  Data are presented as  
log2fo ld  versus contro l  (sh-PKCα  Day zero)  express ion.  Th is  graph represents  data 
of  on ly  one exper iment .   
We found that the effect of PKCα knockdown caused compensatory 
upregulation of AXL receptor tyrosine kinase (AXL 1 and AXL 2) and 
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that this was already signif icant after 5 days of IPTG induction (Fig. 
20). AXL, interestingly, has been described as an essential epithelial-
to-mesenchymal transit ion-induced regulator of breast cancer 
metastasis and patient survival (Gjerdrum et al., 2010). Also AXL 
knockdown is known to impair EGFR signaling (Lauffenburger et al., 
2013 Mil ler et al. I think). Therefore, the observed AXL upregulation 
could serve as a rescue mechanism that “feeds back” to reactivate the 
EGFR pathway. Also, these data suggest that AXL upregulation and 
activation could represent a resistance pathway after EGFR inhibit ion 
that could be potential ly co-targeted for an effective therapy in TNBC 
patients (Fig. 20).  
 
Figure  21:  Graphical  representat ion of  mRNA expression leve ls of  dif fe rent 
RTKs in the  sh-PPP1R14D knockdown in MDA-MB-231 ce l ls .  Data are presented 
as log2fo ld  versus contro l  (sh-PPP1R14D Day zero)  express ion.  Th is  graph 
represents  data of  on ly  one exper iment .   
When we knocked down PPP1R14D, a different RTK expression pattern 
was observed (Fig. 21) . We found that the Fibroblast Growth Factor 
Receptor (FGFR) family was upregulated immediately after the short-
term (5 days) IPTG induction. However, only the expression of FGFR2 
sustained itself after 35 days of sh-PPP1R14D knockdown.   
 
Additionally, the expression levels of Discoidin Domain Receptor 
Tyrosine kinase (DDR1 and DDR2) and ERBB3/HER3 were also found 
increased at the mRNA level after 35 days of IPTG induction.  
The FGFR and DDR family are described as potential biomarkers in 
treatment strategies of TNBC subtypes (Lehmann et al., 2014) and are 
currently being considered as novel targets in TNBC.  
 
Knockdown of PKCα and PPP1R14D was confirmed to validate the 
experiment. However, i t is interesting to note that both gene 
knockdowns showed upregulation of distinct receptor tyrosine kinases 
(RTKs); this further highlights the heterogeneity of TNBC cells. For 
example, when we knockdown PKCα, we do not detect upregulation of 
any of the FGFR, DDR or HER3 receptors; similarly the PPP1R14D 
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knockdown did not result in any increase of the mRNA expression 
levels of AXL receptor tyrosine kinases (Fig. 20 and Fig. 21). 
 
Since we found that knockdown of both, PKCα and PPP1R14D, 
resulted in upregulation of various RTKs, we next examined the effect 
of these knockdowns on activation of mitogenic pathways.  
 
5.7 PKCα and PPP1R14D phenotypic characteristics 
before IPTG induction in vitro  
The phenotypic characteristics of sh-PKCα and sh-PPP1R14D in MDA-
MB-231 TNBC cells are examined before IPTG induction to determine 
the phosphorylated and total levels of downstream targets of EGFR 
activation. MDA-MB-231 TNBC cells were cultured with puromycin and 
IPTG to the medium to select for shRNA construct expressing cells and 
to induce shRNA expression.  
 
Figure  22:  Quanti f icat ion of  phosphorylated prote in leve ls of  sh-PKCα  and sh-
PPP1R14D MDA-MB-231 ce l ls  be fore  IPTG induction (day ze ro) .  The data are 
presented as % of  contro l  (sh-Co) phosphory la ted prote in  concentrat ions.  The data 
represents  on ly  one exper iment .   
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Figure  23:  Quanti f icat ion of  total  prote in leve ls of  sh-PKCα  and sh-PPP1R14D 
MDA-MB-231 ce l ls  be fore  IPTG induction (day ze ro) .  The data are presented as 
% of  contro l  (sh-Co) to ta l  prote in  concentrat ions.  The data represents  on ly  one 
exper iment .   
Extracellular signal-Regulated Kinases (ERKs), Protein Kinase B 
(PKB/Akt) and Signal Transducer and Activator of Transcription 3 
(STAT3), al l  downstream effectors of EGFR were analyzed (Fig. 22 
and Fig. 23). 
 
We examined the total levels of ERK1/2, STAT-3 and AKT as a control 
for their phosphorylated counterparts.  
We also elucidate the effect of the IPTG induced PKCα and PPP1R14D 
MDA-MB-231 cells on the activation of mitogenic pathways over t ime. 
 
5.8 Effects of IPTG induced PKCα and PPP1R14D 
knockdown on kinase phosphorylation  
The effect of IPTG induced PKCα and PPP1R14D knockdown in MDA-
MB-231 cells were examined by supplementing the cells with IPTG-
containing media (100mM) for a period of 5-35 days.  
 
The cells were trypsinized before plating on every f irst day of the 5-day 
time-course and the media was changed every second day. Every f i f th 
day unti l  the 35th day, samples of the cells were lysed and checked by 
immunoblot analysis.  
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Figure  24:  Quanti f icat ion of  phosphorylated prote in leve ls of  PKCα  
knockdown in MDA-MB-231 ce l ls  with IPTG induction (day 5 to day 35) .  The 
data are presented as  % of  contro l  (PKCα  Day 0)  phosphory la ted prote in  
concentrat ions.  The data represents  on ly  one exper iment .   
Figure  25:  Quanti f icat ion of  phosphorylated prote in leve ls of  PPP1R14D 
knockdown in MDA-MB-231 ce l ls  with IPTG induction (day 5 to day 35) .  The 
data are presented as  % of  contro l  (PPP1R14D Day 0)  phosphory la ted prote in  
concentrat ions.  The data represents  on ly  one exper iment .   
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Figure  26:  Quanti f icat ion of  phosphorylated prote in leve ls of  sh-Co in MDA-
MB-231 ce l ls  with IPTG induction (day 5 to day 35) .  The data are presented as  
% of  contro l  (sh-Co Day 0)  phosphory la ted prote in  concentrat ions.  The data 
represents  on ly  one exper iment .   
Both IPTG induced PKCα and PPP1R14D knockdown in MDA-MB-231 
cells, as expected showed very l i t t le to negligible EGFR 
phosphorylation and AKT signaling (Fig. 24 and Fig. 25) as compared 
to sh-Co (Fig. 26).  
Phosphorylated ERKs and STAT-3 were found to be stable all along 
the IPTG time-course, which confirmed the activity of alternative 
receptor tyrosine kinases (RTKs) in the activation of these mitogenic 
pathways (Fig. 24 and Fig. 25). 
Further experimentation for metastasis could be carried out with the 
induced knockdown of PKCα and PPP1R14D in the MDA-MB-231 cell 
l ine to determine the role of EGF ligand regulators in the activation of 
growth factor signaling pathways in vivo.  
The upregulated RTKs which were found in both PKCα/PPP1R14D 
knockdown tumors could be harnessed for better targeting of the 
ADAM17/EGFR ligand axis in combination therapy.  
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6 Conclusion   
 
This thesis justif ied that Protein Kinase C (PKC) activity is essential in 
the regulation of ADAM17 mediated EGF ligand cleavage. Combination 
therapies may play a crit ical role in tr iple negative breast cancer and 
metastasis by circumventing resistance to EGFR targeting, for example 
as proposed here by the ADAM17/EGF ligand cleavage regulator 
targeting. I conclude here why targeting PKCα  and PPP1R14D, the 
ADAM 17 cleavage regulators studied in my master’s thesis, can 
prevent the observed negative side effects of broad-spectrum 
metalloprotease inhibitors in patients, which were due to non-selective 
substrate cleavage inhibit ion.  
 
The first experiment to examine the effect of enzyme inhibitors on 
basal and phorbol ester-induced ADAM17-mediated substrate cleavage 
revealed that the shedding regulation occurs on the substrate level. In 
l ine with the observation, when the same inhibitors were tested on EGF 
receptor activation in vitro, i t  provided us with the solid data that EGFR 
phosphorylation as well as its downstream targets directly depends on 
protein kinase C (PKC) isoforms.  Thus, i t has been successfully 
shown that cleavage of ADAM17 substrates or EGF l igand release is 
inhibited in vitro in a substrate specif ic manner.  
 
In addition, PKC involvement has also been supported by other 
f indings. Knockdown of PKCα  and PPP1R14D in MDA-MB-231 cells 
also demonstrated reduced migration and invasion, thus confirming 
that TNBC relevant cellular responses depend on protein kinase C. The 
PPP1R14D knockdown greatly diminished growth and proliferation of 
cancer cells. 
 
Although the knockdown of PKCα  and PPP1R14D in MDA-MB-231 cells 
detected upregulation of distinct receptor tyrosine kinases (RTKs), this 
aspect could be harnessed for better targeting of the ADAM17/EGFR 
ligand axis in combination therapy.  
 
As a future direction, the role of EGF ligand cleavage regulators in the 
activation of growth factor signaling pathways can be investigated via 
experimentation for metastasis in vivo. This could be used in 
combination with direct EGFR targeting for better therapeutic benefit.  
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